165 related articles for article (PubMed ID: 19082825)
21. A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer.
Martin LK; Grecula J; Jia G; Wei L; Yang X; Otterson GA; Wu X; Harper E; Kefauver C; Zhou BS; Yen Y; Bloomston M; Knopp M; Ivy SP; Grever M; Bekaii-Saab T
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e475-81. PubMed ID: 22818416
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
Sayar H; Shen Z; Lee SJ; Royce M; Rabinowitz I; Lee F; Smith H; Eberhardt S; Maestas A; Lu H; Verschraegen C
Invest New Drugs; 2009 Apr; 27(2):153-8. PubMed ID: 18773144
[TBL] [Abstract][Full Text] [Related]
23. The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.
Choi BS; Alberti DB; Schelman WR; Kolesar JM; Thomas JP; Marnocha R; Eickhoff JC; Ivy SP; Wilding G; Holen KD
Cancer Chemother Pharmacol; 2010 Oct; 66(5):973-80. PubMed ID: 20127092
[TBL] [Abstract][Full Text] [Related]
24. Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors.
Bailey HH; Alberti DB; Thomas JP; Mulkerin DL; Binger KA; Gottardis MM; Martell RE; Wilding G
Clin Cancer Res; 2007 Jun; 13(12):3623-9. PubMed ID: 17510207
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.
Androulakis N; Kouroussis C; Mavroudis D; Kakolyris S; Souglakos J; Agelaki S; Kalbakis K; Malas K; Pallis A; Samonis G; Georgoulias V
Eur J Cancer; 2002 Oct; 38(15):1992-7. PubMed ID: 12376203
[TBL] [Abstract][Full Text] [Related]
26. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
28. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G
Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855
[TBL] [Abstract][Full Text] [Related]
29. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK
Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535
[TBL] [Abstract][Full Text] [Related]
30. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.
O'Brien MER; Sarker D; Bhosle J; Thillai K; Yap TA; Uttenreuther-Fischer M; Pemberton K; Jin X; Wiebe S; de Bono J; Spicer J
Cancer Chemother Pharmacol; 2018 Nov; 82(5):757-766. PubMed ID: 30088048
[TBL] [Abstract][Full Text] [Related]
31. Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies.
Wesolowski R; Peereboom D; Weiss P; Elson P; Thomas Budd G
Invest New Drugs; 2010 Aug; 28(4):502-8. PubMed ID: 19434371
[TBL] [Abstract][Full Text] [Related]
32. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
[TBL] [Abstract][Full Text] [Related]
33. A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors.
Mascarenhas L; Malogolowkin M; Armenian SH; Sposto R; Venkatramani R
Pediatr Blood Cancer; 2013 Jul; 60(7):1103-7. PubMed ID: 23335436
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.
Fracasso PM; Blum KA; Tan BR; Fears CL; Bartlett NL; Arquette MA; Clark RS
Cancer; 2002 Nov; 95(10):2223-9. PubMed ID: 12412177
[TBL] [Abstract][Full Text] [Related]
35. Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
Gojo I; Tidwell ML; Greer J; Takebe N; Seiter K; Pochron MF; Johnson B; Sznol M; Karp JE
Leuk Res; 2007 Sep; 31(9):1165-73. PubMed ID: 17324462
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of pazopanib plus TH-302 in advanced solid tumors.
Riedel RF; Meadows KL; Lee PH; Morse MA; Uronis HE; Blobe GC; George DJ; Crawford J; Niedzwiecki D; Rushing CN; Arrowood CC; Hurwitz HI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):611-619. PubMed ID: 28238078
[TBL] [Abstract][Full Text] [Related]
37. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors.
Kalbakis K; Pappas P; Kouroussis C; Vamvakas L; Kalykaki A; Vardakis N; Nikolaidou M; Marselos M; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2008 Aug; 62(3):449-56. PubMed ID: 17960381
[TBL] [Abstract][Full Text] [Related]
38. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.
Landrum LM; Brady WE; Armstrong DK; Moore KN; DiSilvestro PA; O'Malley DM; Tenney ME; Rose PG; Fracasso PM
Gynecol Oncol; 2016 Feb; 140(2):204-9. PubMed ID: 26616225
[TBL] [Abstract][Full Text] [Related]
39. A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin.
Brana I; Ocana A; Chen EX; Razak AR; Haines C; Lee C; Douglas S; Wang L; Siu LL; Tannock IF; Bedard PL
Invest New Drugs; 2014 Dec; 32(6):1269-77. PubMed ID: 25213162
[TBL] [Abstract][Full Text] [Related]
40. Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors.
Lockhart AC; Sundaram S; Sarantopoulos J; Mita MM; Wang-Gillam A; Moseley JL; Barber SL; Lane AR; Wack C; Kassalow L; Dedieu JF; Mita AC
Invest New Drugs; 2014 Dec; 32(6):1236-45. PubMed ID: 25117475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
